IL320859A - Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) - Google Patents

Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)

Info

Publication number
IL320859A
IL320859A IL320859A IL32085925A IL320859A IL 320859 A IL320859 A IL 320859A IL 320859 A IL320859 A IL 320859A IL 32085925 A IL32085925 A IL 32085925A IL 320859 A IL320859 A IL 320859A
Authority
IL
Israel
Prior art keywords
serds
treatment
methods
breast cancer
estrogen receptor
Prior art date
Application number
IL320859A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL320859A publication Critical patent/IL320859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL320859A 2022-11-17 2025-05-12 Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) IL320859A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263384170P 2022-11-17 2022-11-17
PCT/EP2023/082015 WO2024105147A1 (en) 2022-11-17 2023-11-16 Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)

Publications (1)

Publication Number Publication Date
IL320859A true IL320859A (en) 2025-07-01

Family

ID=88837606

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320859A IL320859A (en) 2022-11-17 2025-05-12 Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)

Country Status (10)

Country Link
US (1) US20240180893A1 (en)
EP (1) EP4618990A1 (en)
JP (1) JP2025537840A (en)
KR (1) KR20250108718A (en)
CN (2) CN120202005A (en)
AU (1) AU2023379941A1 (en)
IL (1) IL320859A (en)
MX (1) MX2025005711A (en)
TW (1) TW202435871A (en)
WO (1) WO2024105147A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038481A1 (en) * 2023-08-11 2025-02-20 Arvinas Operations, Inc. Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (en) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
UA125824C2 (en) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
TWI702219B (en) 2018-07-12 2020-08-21 美商美國禮來大藥廠 Selective estrogen receptor degraders

Also Published As

Publication number Publication date
US20240180893A1 (en) 2024-06-06
JP2025537840A (en) 2025-11-20
KR20250108718A (en) 2025-07-15
MX2025005711A (en) 2025-06-02
AU2023379941A1 (en) 2025-06-26
EP4618990A1 (en) 2025-09-24
CN120202005A (en) 2025-06-24
TW202435871A (en) 2024-09-16
CN121129851A (en) 2025-12-16
WO2024105147A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
IL290789A (en) Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
SA521430055B1 (en) Processes and compounds for the preparation of selective estrogen receptor degraders
IL312680A (en) Methods for treating cancer
IL284850A (en) Methods of treating breast cancer with tucatinib
IL270716B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
GB201901439D0 (en) Method of predicting survival rates for cancer patients
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
AU2024225706A1 (en) Methods for treating breast cancer
MX2025005711A (en) Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)
CA3273636A1 (en) Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)
IL313886A (en) Processes for the preparation of selective estrogen receptor degraders
IL305780A (en) Methods for the treatment of cancer
PL4294395T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
GB202107994D0 (en) Treatment of cancer
EP4157246B8 (en) Therapeutic combination for the treatment of breast cancer
HK40099193A (en) Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL312155A (en) Method of cancer treatment
GB202016173D0 (en) Demethylation apparatus and cancer therapy apparatus comprising same, and demethylation method and aparatus for cancer therapy using same
HK40075586A (en) Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL314687A (en) Treatment of cancer
IL315444A (en) Expression system for the treatment of cancer
IL282471A (en) Combination immunotherapy for treatment of triple-negative breast cancer
IL279604A (en) Apparatus for selective treatment of tissue
PL3787632T3 (en) Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer
IL272390A (en) Methods of treating cancer